Zacks
Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound?
📊
AI Sentiment
Positive
7/10
- Home
- EXEL
EXEL
Exelixis Inc.
as of 03-13-2026 3:59pm EST
$41.26
+$0.10
+0.24%
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 11.7B | IPO Year: | 2000 |
| Target Price: | $46.45 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.78 | EPS Growth: | 57.95 |
| 52 Week Low/High: | $32.38 - $48.74 | Next Earning Date: | 05-04-2026 |
| Revenue: | $452,477,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 13.66% | Revenue Growth (next year): | 13.73% |
| P/E Ratio: | 14.80 | Index: | N/A |
| Free Cash Flow: | 875.8M | FCF Growth: | +30.42% |
AI-Powered EXEL Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 72.22%
72.22%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Exelixis Inc. (EXEL)
Aftab Dana
Sell
EVP, Research and Development
EXEL Feb 24, 2026
Avg Cost/Share
$44.50
Shares
47,918
Total Value
$2,132,351.00
Owned After
616,106
SEC Form 4
Aftab Dana
Sell
EVP, Research and Development
EXEL Feb 19, 2026
Avg Cost/Share
$44.35
Shares
29,873
Total Value
$1,324,867.55
Owned After
616,106
SEC Form 4
Smith Julie
Sell
Director
EXEL Feb 18, 2026
Avg Cost/Share
$44.40
Shares
64,117
Total Value
$2,849,200.50
Owned After
20,590
Hefti Brenda
Sell
SVP and General Counsel
EXEL Feb 18, 2026
Avg Cost/Share
$44.01
Shares
18,669
Total Value
$821,622.69
Owned After
96,512
SEC Form 4
Haley Patrick J.
Sell
EVP, Commercial
EXEL Feb 17, 2026
Avg Cost/Share
$43.67
Shares
67,814
Total Value
$2,950,941.24
Owned After
446,686
Senner Christopher J.
Sell
EVP and CFO
EXEL Feb 17, 2026
Avg Cost/Share
$43.67
Shares
30,617
Total Value
$1,337,044.39
Owned After
976,092
SEC Form 4
Smith Julie
Sell
Director
EXEL Feb 17, 2026
Avg Cost/Share
$43.33
Shares
42,422
Total Value
$1,838,145.26
Owned After
20,590
SEC Form 4
Senner Christopher J.
Sell
EVP and CFO
EXEL Feb 13, 2026
Avg Cost/Share
$43.00
Shares
34,278
Total Value
$1,473,954.00
Owned After
976,092
SEC Form 4
Eckhardt Sue Gail
Sell
Director
EXEL Feb 13, 2026
Avg Cost/Share
$43.79
Shares
3,856
Total Value
$168,854.24
Owned After
17,524
SEC Form 4
Oliver Bob
Sell
Director
EXEL Feb 13, 2026
Avg Cost/Share
$43.75
Shares
30,250
Total Value
$1,325,339.48
Owned After
21,120
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Aftab Dana | EXEL | EVP, Research and Development | Feb 24, 2026 | Sell | $44.50 | 47,918 | $2,132,351.00 | 616,106 | |
| Aftab Dana | EXEL | EVP, Research and Development | Feb 19, 2026 | Sell | $44.35 | 29,873 | $1,324,867.55 | 616,106 | |
| Smith Julie | EXEL | Director | Feb 18, 2026 | Sell | $44.40 | 64,117 | $2,849,200.50 | 20,590 | |
| Hefti Brenda | EXEL | SVP and General Counsel | Feb 18, 2026 | Sell | $44.01 | 18,669 | $821,622.69 | 96,512 | |
| Haley Patrick J. | EXEL | EVP, Commercial | Feb 17, 2026 | Sell | $43.67 | 67,814 | $2,950,941.24 | 446,686 | |
| Senner Christopher J. | EXEL | EVP and CFO | Feb 17, 2026 | Sell | $43.67 | 30,617 | $1,337,044.39 | 976,092 | |
| Smith Julie | EXEL | Director | Feb 17, 2026 | Sell | $43.33 | 42,422 | $1,838,145.26 | 20,590 | |
| Senner Christopher J. | EXEL | EVP and CFO | Feb 13, 2026 | Sell | $43.00 | 34,278 | $1,473,954.00 | 976,092 | |
| Eckhardt Sue Gail | EXEL | Director | Feb 13, 2026 | Sell | $43.79 | 3,856 | $168,854.24 | 17,524 | |
| Oliver Bob | EXEL | Director | Feb 13, 2026 | Sell | $43.75 | 30,250 | $1,325,339.48 | 21,120 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 10, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 10, 2026 · 100% conf.
AI Prediction BUY
1D
+5.86%
$45.76
Act: -0.67%
5D
+7.88%
$46.63
Act: +2.87%
20D
+7.77%
$46.59
Act: -3.42%
Price: $43.23 Prob +5D: 100% AUC: 1.000
0000939767-26-000019
exel-202602102/10/20260000939767false00009397672026-02-102026-02-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 10, 2026
EXELIXIS, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-30235 04-3257395
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
1851 Harbor Bay Parkway Alameda, California 94502 (Address of principal executive offices) (Zip Code)
(650) 837-7000 (Registrant’s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock $0.001 Par Value per ShareEXELThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On February 10, 2026, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter and full year ended January 2, 2026 and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Exelixis, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit NumberExhibit Description
99.1Press Release issued February 10, 2026
104Cover Page Interactive Data FileThe cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EXELIXIS, INC.
February 10, 2026/s/ Brenda J. Hefti
DateBrenda J. Hefti Senior Vice President and General Counsel
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYJan 12, 2026 · 100% conf.
AI Prediction BUY
1D
+5.86%
$45.76
Act: -0.67%
5D
+7.88%
$46.63
Act: +2.87%
20D
+7.77%
$46.59
Act: -3.42%
Price: $43.23 Prob +5D: 100% AUC: 1.000
0000939767-26-000003
exel-202601110000939767false00009397672026-01-112026-01-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 11, 2026
EXELIXIS, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-30235 04-3257395
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
1851 Harbor Bay Parkway Alameda, California 94502 (Address of principal executive offices) (Zip Code)
(650) 837-7000 (Registrant’s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock $0.001 Par Value per ShareEXELThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On January 11, 2026, Exelixis, Inc. (Exelixis or the Company) issued a press release announcing its preliminary unaudited financial results for the fiscal year ended January 2, 2026, providing financial guidance for the fiscal year ending January 1, 2027, and delivered an update on its business. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The preliminary unaudited financial results contained in the press release do not present all information for an understanding of Exelixis’ financial condition as of January 2, 2026 and its results of operations for the fiscal year ended January 2, 2026. The audit of Exelixis’ financial statements for the fiscal year ended January 2, 2026 is ongoing and could result in changes to the information in the press release. The press release also announced that Exelixis will report its audited financial results for the fiscal year ended January 2, 2026 on February 10, 2026.
The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission (SEC) made by Exelixis, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit NumberExhibit Description
99.1Press Release dated January 11, 2026
104Cover Page Interactive Data FileThe cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EXELIXIS, INC.
January 12, 2026/s/ Brenda Hefti
DateBrenda Hefti Executive Vice President and General Counsel
2025 Q3 Q3 2025 Earnings
8-K Nov 4, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 4, 2025
0000939767-25-000127
exel-202511040000939767false00009397672025-11-042025-11-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 04, 2025
EXELIXIS, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-30235 04-3257395
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
1851 Harbor Bay Parkway Alameda, California 94502 (Address of principal executive offices) (Zip Code)
(650) 837-7000 (Registrant’s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock $0.001 Par Value per ShareEXELThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On November 4, 2025, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter ended October 3, 2025, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Exelixis, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Item 8.01. Other Events. Stock Repurchase On November 4, 2025, Exelixis announced that the Board of Directors authorized the repurchase of up to $750 million of its common stock before December 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference only with respect to the discussion in the section titled “Stock Repurchase Program.” Item 9.01. Financial Statements and Exhibits. (d) Exhibits.
Exhibit NumberExhibit Description
99.1Press Release issued November 4, 2025
104Cover Page Interactive Data FileThe cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EXELIXIS, INC.
November 4, 2025/s/ Jeffrey J. Hessekiel
DateJeffrey J. Hessekiel Executive Vice President and General Counsel
Latest Exelixis Inc. News
EXEL Breaking Stock News: Dive into EXEL Ticker-Specific Updates for Smart Investing
Compare EXEL vs Leading Stocks
See how EXEL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "EXEL Exelixis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.